PHARMASSET
Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replica... tion. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.
PHARMASSET
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1987-01-01
Address:
Princeton, New Jersey, United States
Country:
United States
Website Url:
http://www.pharmasset.com
Total Employee:
5001+
Status:
Closed
Contact:
+1 650-574-3000
Email Addresses:
[email protected]
Total Funding:
81.7 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Zoom Video Conferencing Zoom Proofpoint NetNames DNS
Current Advisors List
Founder
Stock Details
Investors List
MDS Capital
MDS Capital investment in Series D - Pharmasset
MPM Capital
MPM Capital investment in Series D - Pharmasset
Bank of America Securities
Bank of America Securities investment in Series D - Pharmasset
Techno Venture Management
Techno Venture Management investment in Series D - Pharmasset
CDIB BioScience Ventures
CDIB BioScience Ventures investment in Series D - Pharmasset
Burrill and co
Burrill and co investment in Series D - Pharmasset
Techno Venture Management
Techno Venture Management investment in Series C - Pharmasset
MPM Capital
MPM Capital investment in Series C - Pharmasset
MPM Capital
MPM Capital investment in Series B - Pharmasset
DuPont
DuPont investment in Series A - Pharmasset
Official Site Inspections
http://www.pharmasset.com
- Host name: 165.160.15.20
- IP address: 165.160.15.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
